Emel Başak Gencer Akçok

Emel Başak Gencer Akçok

Auto-generated profile, based on publicly available information

Emel Başak Gencer Akçok

Abdullah Gul University, Faculty of Life and Natural Sciences, Molecular Biology and Genetics Department, Kayseri, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MYMünevver Yenigül
Münevver Yenigül
IAİsMail Akçok
İsMail Akçok
EAEmel Başak Gencer Akçok
Emel Başak Gencer Akçok

8 June 2023 in ACS Omega
Verified
Journal Article
Open access
MYMünevver Yenigül
Münevver Yenigül
EAEmel Başak Gencer Akçok
Emel Başak Gencer Akçok
Cholangiocarcinoma, also known as biliary tract cancer, is an aggressive adenocarcinoma arising from epithelial cells lining the intra- and extrahepatic biliary system. The effects of autophagy modulators and histone deacetylase (HDAC) inhibitors in cholangiocarcinoma are not fully known. It is essential to understand the molecular mechanisms and the effects of HDAC inhibitors in the context of cholangiocarcinoma. The antiproliferative effect of different HDAC inhibitors and autophagy modulation was investigated by the MTT cell viability assay in TFK-1 and EGI-1 cholangiocarcinoma cell lines. Combination indexes were calculated using CompuSyn software. Consequently, apoptosis was detected by Annexin V/PI staining. The effect of the drugs on the cell cycle was measured by the propidium iodide staining. The HDAC inhibition was confirmed via acetylated histone protein levels by western blotting. HDAC inhibitors, MS-275 and romidepsin, showed a better synergistic effect with the nocodazole combination. The combination treatment exerted its growth inhibitory effect by cell cycle arrest and induction of apoptosis. The cell cycle analysis of the combination treatment showed that the S phase and G2/M phase were achieved. Moreover, the necrotic and apoptotic cell population increased after single HDAC inhibitors and combination treatment. The anti-cancer effect of HDAC inhibitors is revealed by acetylation levels of histones. While acetylation levels were increased in response to HDAC inhibitors and autophagy modulator combinations, the HDAC expression decreased. This study highlights the importance of the combination of HDAC inhibition and autophagy modulators and demonstrates a synergistic effect, which could be a promising therapy and novel treatment approach for cholangiocarcinoma.

26 December 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
MŞMerve Şansaçar
Merve Şansaçar
HSHelin Sağır
Helin Sağır
EAEmel Başak Gencer Akçok
Emel Başak Gencer Akçok

13 May 2024 in Molecular Diversity
Verified
Journal Article
Open access
PDF file
EAEmel Başak Gencer Akçok
Emel Başak Gencer Akçok
HGHüseyin Güner
Hüseyin Güner
IAİsMail Akçok
İsMail Akçok
There are many genes that produce proteins related to diseases and these proteins can be targeted with drugs as a potential therapeutic approach. Recent advancement in drug discovery techniques have created new opportunities for treating variety of diseases by targeting disease-related proteins. Structure-based drug discovery is a faster and more cost-effective approach than traditional methods. SHP2 phosphatase, encoded by the PTPN11 gene, has been the focus of much attention due to its involvement in many types of diseases. The biological function of SHP2 is enabled mostly by protein–protein interaction through its SH2 domains. In this study, we report the identification of a potential small molecule inhibitor for the N-SH2 domain of SHP2 by structure-based drug discovery approach. We utilized molecular docking studies, followed by molecular dynamics simulations and MM/PBSA calculations, to analyze compounds retrieved from the Broad's Drug Repurposing Hub and ZINC15 databases. We selected 10 hit compounds with the best docking scores from the libraries and examined their binding properties in the N-SH2 domain. We found that compound CID 60838 (Irinotecan) was the most suitable compound with a binding free energy value of − 64.45 kcal/mol and significant interactions with the target residues in the domain. Graphical abstract


7 March 2024
Verified
Book Chapter
Closed access
PDF file
MŞMerve Şansaçar
Merve Şansaçar
EAEmel Başak Gencer Akçok
Emel Başak Gencer Akçok